Novel immunotherapy shows promise treating patients with leukemia at high-risk of relapse.
Hematology
Latest News
Advertisement
CME Content
Advertisement
Top news of the week in oncology and cancer drug development.
Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.
Switching Tasigna elicited a long-term response rate in patients with leukemia even after discontinuing treatment.
Switching from Glivec to Tasigna elicited a long-term response rate in patients with leukemia.
Lenalidomide (Revlimid) could potentially offer clinical benefits to patients with multiple myeloma.
Lenalidomide (Revlimid) could potentially offer clinical benefits to patients with multiple myeloma.
Checkpoint inhibitor resistance remains an issue in cancer therapy.
Top news of the week in oncology and cancer drug development.
Myeloma Genome Project to create the largest dataset of molecular profiling for patients with multiple myeloma.
Partnership between Clearbrdige BioMedics and John Wayne Cancer Institute will initially focus on melanoma.
Trisenox is the first approved acute leukemia treatment that is chemotherapy-free.
Top news of the week in oncology and cancer drug development.
Ninlaro regimen increased progression-free survival by 40% in patients with multiple myeloma.
Top news of the week in oncology and cancer drug development.
Top news of the week in oncology and cancer drug development.
Promising data on pediatric relapsed/refractory acute lymphoblastic leukemia to be presented.
Collaboration will examine potential opportunities for combining daratumumab and carfilzomib for the treatment of cancer.
CD98 molecule could be a potential therapeutic target in AML.
The companies plan to collaborate on clinical trials of a novel combination therapy for multiple myeloma.
Rituximab is a cancer medication that can be used in combination with methotrexate to treat symptoms of adult rheumatoid arthritis.
The FDA has accepted the biologics license application from Genentech for a subcutaneous formulation of rituximab for multiple blood cancer indications.
Top news of the week in oncology and cancer drug development.
Developed countries may be able to assist developing countries in ensuring their drugs are safe.
Xgeva targets the RANK ligand pathways to prevent the creation, function, and survival of osteoclasts.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
2
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
3
Surveys Find Significant Gaps in Public’s Understanding of Shared Decision-Making on Vaccinations
4
Megestrol Acetate’s Role in Early-Stage ER-Positive Breast Cancer
5